Based on the importance of this pathway in cancer progression and availability of targeted therapies against this pathway (Alzahrani, 2019), therapeutic modalities that affect expression of TMPO-AS1 are promising strategies for enhancement of the effects of PI3K/Akt/mTOR-targeting modalities. Here, MTOR is linked to cancer.